[go: up one dir, main page]

WO2011105839A2 - Composition de peau externe et son procédé de production - Google Patents

Composition de peau externe et son procédé de production Download PDF

Info

Publication number
WO2011105839A2
WO2011105839A2 PCT/KR2011/001307 KR2011001307W WO2011105839A2 WO 2011105839 A2 WO2011105839 A2 WO 2011105839A2 KR 2011001307 W KR2011001307 W KR 2011001307W WO 2011105839 A2 WO2011105839 A2 WO 2011105839A2
Authority
WO
WIPO (PCT)
Prior art keywords
extract
weight
parts
composition
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/001307
Other languages
English (en)
Korean (ko)
Other versions
WO2011105839A3 (fr
Inventor
양근영
양재열
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2011105839A2 publication Critical patent/WO2011105839A2/fr
Publication of WO2011105839A3 publication Critical patent/WO2011105839A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/756—Phellodendron, e.g. corktree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/884—Alismataceae (Water-plantain family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Definitions

  • the present invention relates to an ointment for external skin compositions, and more particularly to an external skin composition effective for skin diseases such as atopic dermatitis, athlete's foot, eczema, and a method for producing the same.
  • Atopic dermatitis is an abnormality in the stratum corneum, which is the outermost protective wall of the skin.
  • the main symptoms of atopic dermatitis are erythema, oozing / curst, and edema / papulation. ), Excoriation, lichenification, dryness and the like.
  • atopic dermatitis can be classified into stages of first infancy and second childhood. Infancy symptoms begin 2-3 months after birth, reddening and darkening of the face, spots on the neck, arms and legs, and spreading throughout the infant's body. About 75% of infantile atopic dermatitis is lost within 2 years of age, but about 25% of infants are known to develop childhood atopic dermatitis. In addition, atopic dermatitis, which was not present in infancy, may be newly invented in childhood.
  • atopic dermatitis mainly consists of pharmacotherapy such as steroids, antihistamines and antibiotics.
  • Steroids have anti-inflammatory and immunosuppressive effects and have good effects, but they are harmful to the intestines, kidneys, liver, bones and brain, and often recur when discontinued. It is known to have side effects, such as purpura.
  • the inventors of the present invention have completed the external skin composition of the present invention after a long research effort to solve the above problems fundamentally and to make a treatment measure excellent in treatment effect and remarkably low possibility of recurrence or side effects.
  • the present invention has another object to provide a novel method for producing a skin external composition as described above.
  • sensitized stone gobaekban ( ⁇ ⁇ ), starch, yongban, placenta extract, golden ( ⁇ ; Scutellariae Radix Extract, Yellow White ⁇ ; Phellodendri Cortex Extract, Pruni Cortex Extract, Dictamni Radicis Cortex Extract, Galla Rhois Extract, Sagittariae Herba Extract, ⁇ ⁇ : Contains extracts of Tropaeoli Herba and oil of Badger (Meles meles).
  • the calcite (Calamina) is a collection of a single mineral consisting of a carbonate mineral tungsten or a smelt or a collection of multi-mineral mainly smelt.
  • the Alum is a crystalline powder obtained by processing the sulfate mineral alum.
  • the green spot (Melanterium) is a monoclinic sulfate mineral, the main component is ferrous sulfate (FeSO 4 ⁇ 7H 2 O).
  • the brain ⁇ ; Bomeolum is a white crystal obtained by steam distillation of resin or stems and branches from the stem of the cedar, Dryobalanops aromatica Gaertner (Cerebral Fragrance and Dipterocarpaceae).
  • Nogamseok, Gobaekban, green spot used as the composition of the present invention have been used for the purpose of improving and treating the symptoms of various diseases of the human body since ancient times, and the stability of the human body has been verified, and the brain is a processed product obtained from cedar. Also, the stability of the human body has been verified.
  • the sensitized stone, baekban, green spots can be pulverized and used in powder form.
  • the particle size of the powder is 300 to 500 mesh. That is, it is possible to use a powder that passes through the mesh 300 mesh sieve and does not pass through the 500 mesh sieve.
  • the fine particles having a particle diameter of 500 mesh sieve may be absorbed by the skin or may block pores, and the coating particles may not have good coating feeling.
  • the head can be used as a powder (jin) or powdered, or pulverized with the minerals.
  • Badger oil can be produced by capturing badgers or by purchasing commercially available products.
  • placenta extracts include extracts obtained by immersion extraction with water and / or organic solvents from human placenta, such as humans, monkeys, cows, pigs, sheep, and rats, and filtering residue, solvent removed from these extracts, or fine powders thereof Or a solution obtained by dissolving, dispersing, or diluting the extract or the solvent remover by using a suitable solvent. Specifically, it is marketed as a placental extract of water solubility or oil availability.
  • the golden extract is a golden solvent extract
  • the yellowish white extract is a yellowish white solvent extract
  • the bark extract is a solvent extract of hupi
  • the ringworm extract is a solvent extract of ringworm skin
  • It is a solvent extract of the gall bladder.
  • Sujago extract is a solvent extract of Sujago
  • a nasturtium extract is a solvent extract of nasturtium.
  • the extract may be extracted with water or an organic solvent, or a mixed solvent thereof.
  • the organic solvent may be any solvent that can be used usually, preferably a polar solvent such as C1-4 alcohol (for example, methanol, ethanol, etc.) or a mixture thereof may be used.
  • the extraction can be carried out by conventional methods such as hot water extraction, it can be used by lyophilizing the extract.
  • the extract can be used more purified by conventional fractionation or chromatography.
  • composition of the present invention has an effect on skin diseases, and has an effective effect on atopic dermatitis, athlete's foot, eczema and the like.
  • the present invention provides a method for improving atopic dermatitis and administering the composition to a subject.
  • the herbal extracts and minerals used as active ingredients of the composition for external application of the skin of the present invention have been shown to be effective in improving and treating various diseases and symptoms of the human body as described above, but this is used in the same composition as the present invention, which is atopic. It is not known at all to have the effect of greatly improving dermatitis.
  • the external composition for skin according to the present invention can be used for the purpose of improving the symptom of skin diseases such as atopic dermatitis and the treatment and prevention of recurrence, and the formulation is not particularly limited.
  • the external composition of the present invention may be provided as a functional cosmetic composition for the purpose of improving the symptoms of the above-described skin diseases, and may also be provided as a pharmaceutical composition for the purpose of treating and preventing recurrence of the skin diseases.
  • the present invention is provided as a functional cosmetic composition, for example, in a soft cosmetics, nourishing cosmetics, massage creams, nutrition creams, packs, gels, essences or formulations of skin adhesive type cosmetics, or lotions, ointments, gels, creams, It may be formulated into a transdermal dosage form such as a patch or spray.
  • the present invention when the present invention is provided in a pharmaceutical composition, it may be used in the form of a pharmaceutically acceptable salt.
  • the salt is not particularly limited as long as it is pharmaceutically acceptable, and for example, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, hydrobromic acid, formic acid, acetic acid, tartaric acid, lactic acid, citric acid, fumaric acid, maleic acid, succinic acid, methanesulfonic acid , Acid addition salts formed by benzenesulfonic acid, toluenesulfonic acid, naphthalenesulfonic acid and the like can be used.
  • base addition salts such as sodium hydroxide, potassium hydroxide, triethylamine, tert-butylamine can also be used.
  • the external skin pharmaceutical composition according to the present invention may be a base, absorption accelerator, moisturizer, thickener, emulsifier, colorant, fragrance, antioxidant, stabilizer, etc. Fungicides, preservatives and the like can be used. Furthermore, it may be preferably formulated according to each disease or component by any suitable method in the art or using methods disclosed in Remington's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA.
  • examples of the external base include white petrolatum, cetanol, stearyl alcohol, stearic acid, bleached beeswax, liquid paraffin, lauromacrogol, squalane, squalene, lanolin, isobutyl millystinate, medium-chain fatty acid triglycerides, and the like. Can be.
  • absorption accelerators examples include urea, crotamiton, diethyl sebacate, and diisopropyl adipic acid.
  • moisturizing agent examples include polyhydric alcohols such as glycerin, sorbitol, propylene glycol, 1,3-butanediol, sodium pyrrolidone carboxylate and sodium hyaluronate.
  • polyhydric alcohols such as glycerin, sorbitol, propylene glycol, 1,3-butanediol, sodium pyrrolidone carboxylate and sodium hyaluronate.
  • Thickeners include gum arabic, guar gum, locust bean gum, carrageenan, carboxymethyl cellulose, carboxymethyl cellulose, sodium, polyacrylates, polyacrylic acid esters, natural latex, vinyl acetate resin emulsion, polyvinyl alcohol, hydroxypropyl cellulose, Hydroxypropyl methyl cellulose etc. are mentioned.
  • Emulsifiers include glycerin fatty acid esters, sucrose fatty acid esters (sugar esters), sorbitan fatty acid esters, propylene glycol fatty acid esters, lecithin, polyoxyethylene fatty acid esters, polyoxyethylene castor oil, polyoxyethylene hardened castor oil, polyoxyethylene alkyl Ether, polyoxyethylene sorbitan fatty acid ester, sodium lauryl sulfate and the like.
  • fragrance examples include eucalyptus oil, lavender oil, menthol, peppermint oil, rose oil, orange oil, cherry flavor, fruit flavor, vanillin and vanilla flavor.
  • Antioxidants include L-ascorbic acid, ascorbic acid stearate, ascorbic acid palmitate, sodium ascorbate, erythorbic acid, sodium erythorbate, isopropyl citrate, dl- ⁇ -tocopherol, dl- ⁇ -tocopherol, dibutylhydride Oxytoluene (BHT), butylhydroxyanisole (BHA), and the like, but among them, ascorbic acid palmitate, ascorbic acid stearate, L-ascorbic acid, dl- ⁇ -tocopherol, d1- ⁇ -tocopherol and the like, Or combinations thereof.
  • BHT butylhydroxyanisole
  • stabilizer examples include polysorbate, polyethylene glycol, ethanol, acetone, hard silicic anhydride, EDTA, and the like.
  • preservative examples include paraoxybenzoic acid esters, benzalkonium chloride, sorbic acid, phenol, chlorobutanol, chlorocresol, benzyl alcohol, and the like.
  • the external composition for skin of the present invention may simultaneously contain an active ingredient such as a drug that has been conventionally used for the treatment of dermatitis and allergic skin diseases, such as steroids, anti-allergic agents, immunosuppressants, and anti-inflammatory drugs. have.
  • an active ingredient such as a drug that has been conventionally used for the treatment of dermatitis and allergic skin diseases, such as steroids, anti-allergic agents, immunosuppressants, and anti-inflammatory drugs. have.
  • the content of the above-described composition may vary widely depending on the dosage form and is in accordance with conventional methods. However, preferred component ratios are given below.
  • compositions according to the invention may be administered parenterally, transdermal administration is preferred, in particular topical application is most preferred.
  • It may be formulated in a conventional manner using solid or liquid excipients or diluents suitable for topical application.
  • it may be any suitable formulation such as ointment, cream, injection, powder, granules, tablets and the like.
  • the dosage of the pharmaceutical composition according to the present invention may vary over a wide range depending on the symptoms, the area of the onset site, the age, the weight, the dosage form of the medicament, etc., preferably, 0.001 to 1000 mg / kg ⁇ day It is applied directly to the affected area by dividing once or several times a day within the range.
  • the optimal dosage to be administered can be readily determined by one skilled in the art and includes the type of disease, the severity of the disease, the amount of active ingredients and other ingredients contained in the composition, the type of formulation, and the age, weight, general health of the patient, It can be adjusted according to various factors including sex and diet, time of administration, and the rate of secretion of the composition, the duration of treatment, and the drugs used concurrently.
  • compositions according to the present invention may be administered alone or together with other agents or together to assist other agents.
  • other components other than the above-mentioned essential components can be suitably selected and blended by those skilled in the art according to the formulation of the external preparation or the purpose of use.
  • composition according to an embodiment of the present invention with respect to 100 parts by weight of the sensitized stone, 5 to 50 parts by weight of high white spots, 30 to 100 parts by weight of green spots, 5 to 50 parts by weight of pinion, 5 to 50 parts by weight of placenta extract Wealth, golden and yellow and white and skin and ringworm and the gall of the mixed extract 20 to 100 parts by weight, 20 to 100 parts by weight of the mixed extract of Sago and nasturtium and badger oil may contain 100 to 500 parts by weight. If the green spots and the brain is too small, weakness, too much minerals to reduce the absorption of the composition in the case of the green starch, there is a disadvantage in the case of the brain smells bad smell.
  • the high alum is 7-40 parts by weight, more preferably 8-30 parts by weight. If too high alum is too weak, weakness is contained, and if too much alum is contained, skin is generated, and when it is 50 parts by weight or more, the composition of the present invention is hardly absorbed on the skin and becomes hard.
  • the mixed extract of golden and yellow and white and white skin and pine gland and five ginseng, and the mixed extract of sojago and nasturtium are too small, weakness, too much occurs a problem that is not well mixed with badger oil. More preferably, 30-80 parts by weight of the mixed extract of gold, yellowish white, humus, ringworm, and gall bladder is good with respect to 100 parts by weight of unreacted stone, and 30-80 parts by weight of the mixed extract of sujago and nasturtium. .
  • composition of the present invention may further comprise a herbal extract, in addition to the above-mentioned effective ingredient, showing an additional atopic dermatitis improving action.
  • a herbal extract in addition to the above-mentioned effective ingredient, showing an additional atopic dermatitis improving action.
  • high ginseng extract, changja extract, cheoncho extract may be added.
  • composition according to another embodiment of the present invention based on 100 parts by weight of the sensitized stone, 5 to 50 parts by weight of high white spots, 30 to 100 parts by weight of green spots, 5 to 50 parts by weight of pinion extract, 5 to 50 parts by weight of placenta extract 20 to 100 parts by weight of mixed extracts of golden and yellow and white and humus and ringworm and five ginsengs, 20 to 100 parts by weight of mixed extracts of sogo and nasturtium, 100 to 500 parts by weight of badger oil, and 0.5 to 10 parts by weight of gentamicin sulfate Can be.
  • composition according to another embodiment of the present invention based on 100 parts by weight of the sensitized stone, 5 to 50 parts by weight of high white spots, 30 to 100 parts by weight of green spots, 5 to 50 parts by weight of pinion, 5 to 50 parts by weight of placenta extract 20 to 100 parts by weight of a mixed extract of Boo, Golden and Yellow and White Skin and White Pine and Fifty ginseng, 20 to 100 parts by weight of a mixed extract of Sugo and Hannulhwa, Badger oil 100 to 500 parts by weight, and Gentamycin sulfate 0.5 to 10 parts by weight And dipropionate betamethasone 0.1 to 3 parts by weight.
  • the present invention comprises the steps of (a) pulverizing the nitrite, gourd plaque, green macula and chalcedony; (b) immersing the golden, yellowish white, white skin, ringworm and five gall in water and then heating to obtain a hot water extract; (c) soaking water and soaking the nasturtium in water to obtain a hot water extract; (d) mixing badger oil and placental extract to obtain a first mixture; (e) mixing the ground product of step (a) with the hot water extract of step (b) and the hot water extract of step (c) to obtain a second mixture; And (f) mixing the first mixture and the second mixture.
  • the production method of the present invention is as follows, and used in the manufacturing method, sensitized stone, gourd plaque, green spot and green head, golden, yellowish white, white skin, ringworm skin and gall bladder, placental extract, sojago, nasturtium, badger oil is Same as in the composition of the present invention.
  • step (a) with respect to 100 parts by weight of unreacted stone, 5-50 parts by weight, green spots 30-100 parts by weight, brain powder 5-50 parts by weight, pulverized with a pulverizer and then sieved to obtain a particle diameter of 300 to 500 mesh.
  • the crushed product can be prepared.
  • the pulverized product can be prepared independently of each other.
  • step (b) 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5 in weight ratio of gold, yellowish white, leather, ringworm and gall bladder, and 5 to 5 in weight ratio for this mixture.
  • a vacuum cooker or a water bath with a pressure of 1 to 3 kg / cm 2 at a temperature of 90 to 120 ° C. for 2 to 4 hours the solids are filtered off, and then concentrated by heating for about 1 hour.
  • 20 to 120 parts by weight of hot water extracts may be prepared based on 100 parts by weight of no-gem.
  • step (c) after dipping the high water and nasturtization in purified water having a weight ratio of 0.5 to 1.5: 0.5 to 1.5, and having a weight of 2 to 4 times of the mixture, a vacuum cooker having a pressure of 1 to 3 kg / cm 2 After heating for 2 to 4 hours at a temperature of 90 to 120 ° C. in an incubator, filtering the solids and heating and concentrating again for about 40 minutes, 20 to 120 parts by weight of hot water extracts can be prepared with respect to 100 parts by weight of noite. .
  • Badger oil in the step (d) is obtained by placing the fat of badger having a weight of about three times the desired amount on an iron plate or cast plate and extracted by heating to 300 ⁇ 600 °C, by removing impurities with a nonwoven fabric have.
  • Badger oil prepared as described above is 100 to 500 parts by weight with respect to 100 parts by weight of unreacted stone. More preferably, it is 150-250 parts by weight, and the placental extract is mixed therewith to obtain a first mixture.
  • the second mixture obtained by mixing the pulverized mineral obtained in step (a) and the hot water extract obtained in steps (b) and (c), respectively, is mixed with the first mixture in step (d) again.
  • the composition of the present invention can be completed. Mixing may be mixed using a known mixer or the like, and the finished product ointment may be prepared by adding a step of packaging into a product.
  • Method for producing a composition according to an embodiment of the present invention as described above is to complete the composition of the formulation of the ointment, for other formulations can be prepared by the person skilled in the art appropriately selected to suit the desired formulation.
  • the first mixture may be obtained by mixing 0.5-10 parts by weight of gentamicin sulfate and placental extract with respect to 100 parts by weight of noduxite to the badger oil prepared in step (d).
  • the novel composition of the present invention has an excellent effect on improving the symptoms of atopic dermatitis. In addition, it will greatly contribute to the treatment of atopic dermatitis as well as similar skin diseases such as contact dermatitis and psoriasis. In addition, side effects and recurrence are extremely low.
  • Placenta extract was prepared by purchasing 15g of Dongduk Pharm.
  • 520g of badger oil was obtained by removing 520g of fat from a badger, placing it on an iron plate, heating it at 500 ° C for 2 hours, and then removing impurities with a nonwoven fabric.
  • Example 1 100 serious patients (5-50 years old male and female) suffering from atopic dermatitis were tested for atopic dermatitis improvement effect for 12 weeks using the composition of Example 1 and the compositions of Comparative Examples 1 to 4.
  • the composition of Example 1 was to be used for 60 people, each of the compositions of Comparative Examples 1 to 4 was to be used for 10 people, was applied twice a day thinly applied to the affected area for 12 weeks. If the symptom disappeared during the test, it was no longer used.
  • Example 1 has an excellent effect of improving atopic dermatitis compared to the cases of Comparative Examples 1 to 4.
  • Example 1 On the other hand, among the subjects using the composition of Example 1, 21 patients with athlete's foot and 15 patients with eczema were used for athlete's foot and eczema, and the symptoms were reported to be improved.
  • Example 1 To the composition of Example 1, 4 g of gentamicin sulfate (Korea Pharmaceutical Association, Seoul, Korea) was added in (1-6) of Example 1 to complete a composition mixed with gentamicin sulfate. The remaining composition and preparation were the same as in Example 1.
  • Example 1 atopic dermatitis was not significantly improved, did not change, or worsened in 59 panelists.
  • the composition of Example 2 was treated in the same manner as in Experiment 1 to improve the symptoms of atopic dermatitis. It measured, and the result is shown in Table 2.
  • cases of recurrence or side effects after 6 months were examined, but no recurrence or side effects were investigated. That is, in the case of a composition in which an appropriate amount of gentamicin sulfate (pharmacopoeia) was mixed with the composition of Example 1, an improved therapeutic effect was shown.
  • Example 2 of the present invention dipropionate betamethasone (Korea Pharmaceutical Association, Seoul, South Korea) 0.1g is added in the step corresponding to (1-6) of Example 1 to dipropionate betamethasone composition was completed. The remaining composition and preparation were the same as in Example 2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition de peau externe. La composition de la présente invention peut comprendre par rapport à 100 parties en poids de calamine : de 5 à 50 parties en poids de sulfate de potassium et d'aluminium, de 30 à 100 parties en poids de mélantérite, de 5 à 50 parties en poids de bornéol, de 5 à 50 parties en poids d'extrait de placenta, de 20 à 100 parties en poids d'un extrait mélangé de racine de Scutellaria baicalensis, d'écorce de Phellodendron amurense, de cortex de Betulae, d'écorce de racine de Dictamnus, et de galle de Rhus, de 20 à 100 parties en poids d'un extrait mélangé de Sagittariae aginashi et de Nasturtium, et de 100 à 500 parties en poids d'huile de Meles meles. De plus, la composition de peau externe de la présente invention peut être une composition pharmaceutique ou peut être une composition cosmétique.
PCT/KR2011/001307 2010-02-24 2011-02-24 Composition de peau externe et son procédé de production Ceased WO2011105839A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100016551A KR101005972B1 (ko) 2010-02-24 2010-02-24 피부외용 조성물 및 그 제조방법
KR10-2010-0016551 2010-02-24

Publications (2)

Publication Number Publication Date
WO2011105839A2 true WO2011105839A2 (fr) 2011-09-01
WO2011105839A3 WO2011105839A3 (fr) 2012-01-12

Family

ID=43615825

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/001307 Ceased WO2011105839A2 (fr) 2010-02-24 2011-02-24 Composition de peau externe et son procédé de production

Country Status (2)

Country Link
KR (1) KR101005972B1 (fr)
WO (1) WO2011105839A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102526304A (zh) * 2012-01-19 2012-07-04 浙江省农业科学院 一种治疗兔皮肤真菌病的中草药物及治疗方法
CN102716395A (zh) * 2012-06-13 2012-10-10 中国人民解放军总医院 用于皮肤疾病的中药喷雾剂
CN102872158A (zh) * 2012-07-02 2013-01-16 马应龙药业集团股份有限公司 一种治疗湿疹的外用药物组合物及其制备方法
CN104524061A (zh) * 2015-01-05 2015-04-22 于明彩 一种可作多种保健用品的矿植物复方粉体及其制备方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102641373B (zh) * 2012-05-09 2013-12-25 袁培华 一种用于治疗牛皮癣的中药组合物
KR101974145B1 (ko) * 2017-12-22 2019-04-30 한국생명공학연구원 보풀 추출물을 유효성분으로 함유하는 아토피 피부염의 예방, 개선 또는 치료용 조성물
CN112156042B (zh) * 2020-10-16 2023-01-06 肇庆苗和堂医药有限公司 一种洗发水的制作工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR980000460A (ko) * 1996-06-27 1998-03-30 신광호 외피용 약제 조성물
KR0165939B1 (ko) * 1996-06-28 1999-01-15 김박광 구기자 추출물을 함유하는 혈당강하제 조성물 및 구기자 추출물의 제조방법
KR20030055154A (ko) * 2001-12-24 2003-07-02 주식회사 하니로 피부질환 치료용 조성물 및 그 제조방법
KR100682048B1 (ko) * 2005-03-30 2007-02-12 정두수 아토피 치료용 한약조성물
KR100772575B1 (ko) * 2006-02-02 2007-11-02 주식회사 에스티씨나라 생약성분 추출물을 함유하는 피부 외용제 조성물
KR100667182B1 (ko) * 2006-08-08 2007-01-12 주식회사 코스메카코리아 오소리 오일을 함유하는 피부 건조증 개선용 화장료
KR100875577B1 (ko) 2008-06-05 2008-12-23 김길순 아토피 피부염 예방 및 개선용 크림 제조방법
KR20100000026A (ko) * 2008-06-24 2010-01-06 재단법인 제주하이테크산업진흥원 돼지 태반 추출물을 이용한 아토피 피부염 개선용 조성물

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102526304A (zh) * 2012-01-19 2012-07-04 浙江省农业科学院 一种治疗兔皮肤真菌病的中草药物及治疗方法
CN102716395A (zh) * 2012-06-13 2012-10-10 中国人民解放军总医院 用于皮肤疾病的中药喷雾剂
CN102872158A (zh) * 2012-07-02 2013-01-16 马应龙药业集团股份有限公司 一种治疗湿疹的外用药物组合物及其制备方法
CN104524061A (zh) * 2015-01-05 2015-04-22 于明彩 一种可作多种保健用品的矿植物复方粉体及其制备方法

Also Published As

Publication number Publication date
WO2011105839A3 (fr) 2012-01-12
KR101005972B1 (ko) 2011-01-05

Similar Documents

Publication Publication Date Title
KR101812746B1 (ko) 염증 및 말초 통증 감소에 유용한, 에키네시아 안구스티폴리아 및 생강 추출물을 포함하는 제제
WO2011105839A2 (fr) Composition de peau externe et son procédé de production
CN100542585C (zh) 一种具有镇痛和抗炎作用的外用药物组合物
MX2008012654A (es) Composiciones novedosas para trastornos del cabello, y procedimiento de preparacion de las mismas.
WO2010062103A2 (fr) Composition topique pour la peau et son procédé de préparation
US20130337090A1 (en) Plant extracts for treating burns and chronic wounds
KR102067832B1 (ko) 아토피 피부염에 대한 예방 및 치료용 약학 조성물 및 그 제조방법
CN104208153A (zh) 一种治疗皮肤病的中药组合物及其制剂
CN104983844A (zh) 具有粘膜修复功能的组合物配方及其制剂的制备过程
CN105663385B (zh) 一种蒙药镇痛膏及其制备方法
CN1311850C (zh) 治疗肿痛的外用药物组合物
CN108785429B (zh) 一种具有舒缓修复功效的外用中药组合物及其制备方法
CN104324125B (zh) 一种治疗慢性咽炎的中药组合物及其制备方法
WO2017146486A1 (fr) Composition destinée à prévenir ou traiter l'hyperplasie bénigne de la prostate contenant de l'extrait de morus alba linnaeus
CN102008576A (zh) 一种治疗扭伤的外用中药及其制备方法
KR20100026855A (ko) 염증성 피부질환의 예방 또는 치료용 피부 외용제 조성물
WO2019004626A1 (fr) Composition de prévention ou de traitement du syndrome ménopausique, contenant un extrait d'herbe médicinale comme principe actif
CN101904911B (zh) 一种治疗湿疹的外涂药物及其制备方法
CN105687730B (zh) 一种用于局部止痛的复方延胡索中药组合物
CN113318180A (zh) 一种治疗跌打损伤的中药组合物及其制备方法
CN105031380A (zh) 一种用于孕妇口腔局部麻醉的药物及其制备方法
CN117224631B (zh) 一种用于青春期痤疮疾病的中药组合物及其制备方法和应用
CN102600285B (zh) 一种治疗猪传染性萎缩性鼻炎的复方蜂胶组合物及其制备方法
CN112755101B (zh) 一种治疗膝骨关节炎的中药组合物及其应用
CN109568519A (zh) 一种用于湿疹的中药组合物及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11747729

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 31/10/2012

122 Ep: pct application non-entry in european phase

Ref document number: 11747729

Country of ref document: EP

Kind code of ref document: A2